CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical company focused on identifying, enhancing, and monetising high-potential therapeutic assets through a combination of artificial intelligence, solid-form chemistry, and strategic partnerships.
The Company’s model is centred on value creation through intellectual property and out-licensing, rather than traditional capital-intensive drug development. CDT identifies clinically validated or underutilised pharmaceutical assets and enhances them through proprietary solid-form and cocrystallization technologies, generating new compositions of matter with the potential for up to 20 years of additional patent protection.
In parallel, CDT leverages its strategic equity position in Sarborg Limited, an agentic signature intelligence business, to apply advanced AI-driven analysis across its portfolio. Sarborg’s Signature Agent operates at the genomic and pathway level, using connectivity mapping, disease enrichment, and protein-level analysis to rapidly identify high-probability indications, combination strategies, and lifecycle expansion opportunities in minutes rather than years.
This combined approach enables CDT to:
● Identify overlooked or high-value therapeutic indications
● Optimise asset positioning and development strategy
● Generate novel IP through solid-form and combination strategies
● Create structured data packages to support licensing and partnering
CDT’s assets are then positioned for out-licensing to pharmaceutical partners, who undertake late-stage clinical development, regulatory approval, and commercialisation. This model allows CDT to participate in value creation through upfront payments, milestones, and royalties, while maintaining a lean operating structure and capital-efficient approach.
The Company’s current portfolio spans autoimmune diseases, oncology, dermatology, male infertility, and animal health, supported by partnerships including AstraZeneca and Sarborg.
Operating as a multi-pathway value creation platform, CDT combines:
● A portfolio of clinically validated assets
● A growing IP estate driven by solid-form innovation
● Strategic exposure to a high-growth AI platform through Sarborg
This integrated model positions CDT to unlock hidden value across pharmaceutical assets while maintaining speed, flexibility, and strong capital efficiency.